Cell Microarrays versus other methods

Our technology delivers:

  • Highest success rate for identification of specific cell surface targets/receptors
  • Low false positive rates

The main alternatives for identifying receptor interactions have low success rates as they do not provide a natural, human environment for interactions to occur with fully folded proteins. They are also often time consuming and require expensive in-house expertise and equipment.

Due to our high success rates, a major pharmaceutical client has estimated that our service only requires around 10% of the investment that would be needed for them to achieve the same results in-house. Our clients are able to focus on other areas whilst our expert team of scientists work on delivering results in around eight weeks.


Retrogenix’s high rates of success in target deconvolution, receptor identification and off-target screening are due to:

High Success Rates
Expression in human cells results in correct folding and plasma membrane localisation and allows for multimerisation and the detection of interactions mediated by post-translational modifications such as glycosylation.
At >4,500 full-length clones, our microarrays represent around 70% of all known plasma membrane proteins providing the highest likelihood of identifying a ligand’s specific target.
Full-length, non-fused human proteins are expressed in human cells – a real advantage over traditional protein arrays.
Results typically delivered in 6-8 weeks.
Expertise &
Studies are co-designed with clients in order match their needs. Dialogue is maintained throughout and a comprehensive report with data interpretation delivered on completion.
Ligand-receptor interactions around 10 micromolar can be detected even without any amplification strategies. Reproducibility is key, resulting in the detection of specific, biologically-relevant targets.
As the Retrogenix technology detects direct binding of drug to proteins, and is not a competition-based assay, we can discover important allosteric interactions.
Compatible with a range of detection methods including anti-His, anti-Flag, anti-V5, anti-Fc, biotin-streptavidin, directly fluorescently tagged and radiolabeled molecules.

Case Studies

Retrogenix’s results are now supporting patent applications, appearing in peer-reviewed publications and being presented at international conferences.

Find out about how the Retrogenix Technology has been used:

Case Studies


FAQ: “What data will I receive?”

A full report presenting and interpreting the results of the screens is provided at the end of the study. On request, members of the Retrogenix team can also present and discuss the results via a web meeting.

More FAQs

Talk to us about a project
Please leave this field empty.
The University of Sheffield
Aveo Oncology - The Human Response
Theraclone Sciences
Bluebird Bio
The Center for Infectious Disease Research
Compugen Logo
The University of Copenhagen
Lund University
NIH - National Institutes of Health
The University of Pennsylvania
Scripps Florida - The Scripps Research Institute
Peptinnovate Ltd - Unlocking Nature's Potential
Thank you again for your professionalism, for a fine analysis, and for our enjoyable scientific exchanges.
Professor Gunnar Lindahl, Lund University, Sweden